Interim 3-year follow-up data further demonstrate consistent safety and efficacy of the supraciliary MIGS implant Miniject (iStar Medical) in OAG patients, according to data presented at the World Glaucoma Congress. Inder Paul Singh, MD, of the Eye Centers of Racine and Kenosha, Wisconsin, presented efficacy results from 48 patients that reveal a sustained, meaningful 36% reduction in IOP at 3 years with 42% of patients remining medication free. Corneal health and other safety measures were also favorable, according to a company news release, with no serious adverse events related to the device or procedure STAR-GLOBAL study follow-up period.

“The safety and efficacy observed at up to 3-year follow-up is highly encouraging as it demonstrates the sustained and meaningful performance of iStar Medical’s Miniject into the longer term,” Dr. Singh said. “This confirms the consistent safety and efficacy profile Miniject has already shown in previous STAR trials.”